Aura Biosciences, Inc. (AURA)

NASDAQ: AURA · IEX Real-Time Price · USD
7.85
+0.15 (1.95%)
At close: Mar 28, 2024, 4:00 PM
7.69
-0.16 (-2.04%)
After-hours: Mar 28, 2024, 5:00 PM EDT

Company Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.

The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology.

It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial.

The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.

The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences, Inc.
Aura Biosciences logo
Country United States
Founded 2007
IPO Date Oct 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 70
CEO Dr. Elisabet de los Pinos Ph.D.

Contact Details

Address:
80 Guest Street
Boston, Massachusetts 01235
United States
Phone (617)500-8864
Website aurabiosciences.com

Stock Details

Ticker Symbol AURA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $14.00
CIK Code 0001501796
CUSIP Number 05153U107
ISIN Number US05153U1079
Employer ID 32-0271970
SIC Code 2836

Key Executives

Name Position
Dr. Elisabet de los Pinos Ph.D. Founder, Chief Executive Officer, President and Director
Julie B. Feder Chief Financial Officer, Secretary and Treasurer
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer
Patrick Nealon Senior Vice President of Clinical Development Operations
Dr. Bruce Brown M.D. Senior Vice President and Therapeutic Area Head of Urologic Oncology
Dr. Anthony Daniels M.D. Therapeutic Area Head of Ocular Oncology
Dr. Richard Mountfield Ph.D. Senior Vice President of Regulatory Affairs and Quality
Dr. Jill Hopkins M.D. Chief Medical Officer and President of Research and Development

Latest SEC Filings

Date Type Title
Mar 27, 2024 S-3 Registration statement under Securities Act of 1933
Mar 27, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2024 10-K Annual Report
Mar 27, 2024 8-K Current Report
Mar 4, 2024 144 Filing
Feb 23, 2024 144 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 144 Filing
Jan 24, 2024 144 Filing